 Atara Biotherapeutics Inc NASDAQ: ATRA completed the planned Interim Analysis of the ATA188 Phase 2 study EMBOLD in progressive multiple sclerosis patients. The analysis primary focus was on expanded disability status scale EDSS improvement at six months and overall. 